As AMRN stock prices indicates, its no longer enough to get your drug approved, you have to adequately manufacture, market and sell it. This takes time and resources. It will likely be a little while before this drug poses a real threat to sales of Lovaza, unless, of course, AMRN is bought out or drug is licensed to a big pharma partner.
Count on the buyout----there is little infrastructure in place at AMRN to sell this for the indication approved much less further indications in progress! Only question is who will get it and how strong will the patents be!